Compare RNR & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNR | DVA |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 8.4B |
| IPO Year | 1995 | 1995 |
| Metric | RNR | DVA |
|---|---|---|
| Price | $271.98 | $121.51 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 13 | 4 |
| Target Price | ★ $291.73 | $145.00 |
| AVG Volume (30 Days) | 364.7K | ★ 945.5K |
| Earning Date | 01-27-2026 | 10-29-2025 |
| Dividend Yield | ★ 0.59% | N/A |
| EPS Growth | N/A | ★ 5.63 |
| EPS | ★ 34.70 | 9.76 |
| Revenue | $12,214,870,000.00 | ★ $13,317,965,000.00 |
| Revenue This Year | N/A | $6.50 |
| Revenue Next Year | N/A | $2.97 |
| P/E Ratio | ★ $7.79 | $12.43 |
| Revenue Growth | N/A | ★ 5.14 |
| 52 Week Low | $219.00 | $113.97 |
| 52 Week High | $274.80 | $179.60 |
| Indicator | RNR | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 63.63 | 54.23 |
| Support Level | $261.72 | $115.91 |
| Resistance Level | $271.95 | $122.61 |
| Average True Range (ATR) | 4.69 | 2.30 |
| MACD | 0.44 | 0.54 |
| Stochastic Oscillator | 99.76 | 83.43 |
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.